Breast Cancer (Gene Therapy)

Cytokine Producing Cancer Cells Lose Tumorigenicity

Published in Gene Therapy Weekly, January 13th, 2000

Human breast cancer cells engineered to produce IL-2, IL-4 or GM-CSF lose their tumorigenicity in a nude mouse model, report researchers from Japan.

"Human breast cancer cells (OCUB-M), retrovirally transduced with granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-2 (IL-2) or IL-4 gene were examined for their antitumor activities in nude mice," stated T. Maeda and colleagues from Chiba University, School of Medicine, Japan.

Maeda et al. published the results of their study in the International Journal of Oncology ("Loss of Tumorigenicity of Human Breast Cancer Cells Engineered to Produce IL-2, IL-4 or GM-CSF in Nude Mice,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry